Innovations In Clinical Neuroscience

JAN-FEB 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 43 of 53

R E V I E W 44 ICNS Innovations in Clinical Neuroscience • January–February 2018 • Volume 15 • Number 1–2 73. Bruno J, Hosseini S, Kessler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48:329–338. 74. Hosseini S, Koovakkattu D, Kesler S. Altered small- world properties of gray matter networks in breast cancer. BMC Neurol. 2012;12:28. 75. Kesler S, Wefel J, Hosseini S et al. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Scie USA. 2013;110:11600–11605. 76. Phillips K, Jim H, Small B, et al. Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer. 2012;118:1925–1932. 77. Wefel J, Lenzi R, Theriault R, et al. "Chemobrain" in breast cancer? a prologue. Cancer. 2004;101:466– 475. 78. Rodgers J, Morse R, Verrill M, et al. Cognitive functioning in women following adjuvant treatment for breast cancer. J Psychopharmacol. 2003;17:A68. 79. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828–34. 80. Sof fi etti R, KocherM, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of- life results. J Clin Oncol. 2013;31:65–72. 81. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27(1):78–84. 82. Chang E, Wefel J, Hess, K, et al. Neurocognition in patients with brain metastases treated radiosurgery or radiosurgery plus whole-brain irradiation: A randomized controlled trial. Lancet Oncology. 2009;10:1037–1044. 83. Crossen J, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation induced encephalopathy. J Clin Oncol. 1994;12:627–642. 84. Merchant T, Conklin H, Wu S, et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27:3691–3697. 85. Gondi V, Hermann B, Mehta M, Tome W. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85:348–354. 86. Sheline G, Wara W, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215–1228. 87. Meyers C, Brown P. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24:1305–1309. 88. Wefel J, Witgert M, Meyers C. Neuropsychological sequelae of non central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008; 18:121–131. 89. Vardy J, Wefel J, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–629. 90. Harrison J. Measuring cognitive change in Alzheimer's disease clinical drug trials. J Nutr Health Aging. 2007;11:327–329. 91. Harrison J, Minassian S, Jenkins L, et al. (2007). The NTB: A neuropsychological test battery for use in Alzheimer's disease clinical trials. Arch Neurol. 2007; 64:1323–1329. 92. Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with vortioxetine? Intl J Neuropsychopharm. 2016;19:1–6. 93. Ritchie K, Ropacki M, Albala B, et al. Recommended cognitive outcomes in pre-clinical Alzheimer's disease: consensus statement from the European Prevention of Alzheimer's Dementia (EPAD) Project. Alzheimer's and Dementia. 2016;13:186–195. 94. Harrison J. Measuring the mind: Detecting cognitive deficits and measuring cognitive change in patients with depression. In: McIntyre R, Cha D (eds.) Cognitive Impairment in Major Depressive Disorder. Cambridge: Cambridge University Press;2016. 95. Harrison J, Lam R, Baune B, McIntyre R. Selection of cognitive tests for trials of therapeutic agents. Lancet Psychiatry. 2016;8:1–13. 96. Walker L, Wesnes K, Heys S, et al. The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trials using computerized assessments. E Jrnl Cancer. 1996;32A:2275–2283. 97. Kohli S, Fisher S, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009;115:2605–2616. 98. Wesnes K, Edgar C, Brooke, H. The disruptions to cognition, everyday function and quality of life in oncology patients: a therapeutic opportunity. Presented at the 6th annual International Society for CNS Clinical Trials (ISCTM). 2010 February; Washington DC. 99. Gualtieri C, Johnson L. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006;21:623– 643. 100. Meskal I, Gehring K, van der Linden SD, et al. Cognitive improvement in meningioma patients after surgery: clinical relevance of computerized testing. J Neurooncol. 2015;121:617–625. 101. Patel S, Meir A, Fernandez N, et al. Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer. Clin Neuropsychol. 2017;12:1–12. 102. Sands S, Harel B, Savone M, et al. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017;25:449–457. 103. Chan R, McCarthy A, Devenish J, et al. Systematic review of pharmacologic and nonpharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Euro J Cancer. 2015;51:437–450. 104. Gehring K, Roukema J, Sitskoorn M. Review of recent studies on intervention for cognitive deficits in patients with cancer. Expert Adv Anticancer Ther. 2012;12:255–269. 105. Ferguson R, McDonald B, Rocque M, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology. 2012;21:176–186. 106. Sherer M, Meyers C, Bergloff P. Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors. Cancer. 1997;80:250–257. 107. Gehring K, Patwardhan S, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neuro Oncol. 2012;107(1):165–174. 108. Shaw E, Rosdhal R, D'Agostino R Jr, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24:1415–1420. 109. Rapp S, Case L, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33:1653–1659. 110. Lawrence J, Griffin L, Balcueva E, et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2016:10:176–184. 111. Correa D, Kryza-Lacombe M, Baser R, et al. Cognitive effectis of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol. 2016;127:313–319. 112. Brown P, Pugh S, Laak N, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15:1429–1437. ICNS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2018